{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:03:20Z","timestamp":1776927800138,"version":"3.51.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>An increase in the demand for a functional cure has accelerated research on new methods of therapy for chronic hepatitis B, which is mainly focused on restoring antiviral immunity for controlling viral infections. Previously, we had described elongation factor Tu GTP-binding domain containing 2 (EFTUD2) as an innate immune regulator and suggested that it might be an antiviral target.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we generated the Epro-LUC-HepG2 cell model for screening compounds that target EFTUD2. Plerixafor and resatorvid were screened from 261 immunity and inflammation-related compounds due to their ability to highly upregulate EFTUD2. The effects of plerixafor and resatorvid on hepatitis B virus (HBV) were examined in HepAD38 cells and HBV-infected HepG2-NTCP cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The dual-luciferase reporter assays showed that the EFTUD2 promoter hEFTUD2pro-0.5 kb had the strongest activity. In Epro-LUC-HepG2 cells, plerixafor and resatorvid significantly upregulated the activity of the EFTUD2 promoter and the expression of the gene and protein. In HepAD38 cells and HBV-infected HepG2-NTCP cells, treatment with plerixafor and resatorvid strongly inhibited HBsAg, HBV DNA, HBV RNAs, and cccDNA in a dose-dependent manner. Furthermore, the anti-HBV effect was enhanced when entecavir was administered along with either of the previous two compounds, and the effect could be blocked by knocking down EFTUD2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We established a convenient model for screening compounds that target EFTUD2 and further identified plerixafor and resatorvid as novel HBV inhibitors <jats:italic>in vitro<\/jats:italic>. Our findings provided information on the development of a new class of anti-HBV agents that act on host factors rather than viral enzymes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1118801","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:21:05Z","timestamp":1676877665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Plerixafor and resatorvid inhibit hepatitis B virus in vitro by upregulating elongation factor Tu GTP-binding domain containing 2"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinyuan","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruirui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanlong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12876-017-0726-2","article-title":"Upcoming pharmacological developments in chronic hepatitis b: can we glimpse a cure on the horizon","volume":"17","author":"Alonso","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.tim.2018.11.004","article-title":"Advances in analyzing virus-induced alterations of host cell splicing","volume":"27","author":"Ashraf","year":"2019","journal-title":"Trends Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nsmb.3310","article-title":"RNA-Binding protein CPEB1 remodels host and viral RNA landscapes","volume":"23","author":"Batra","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12985-019-1137-5","article-title":"The Epstein-Barr virus EBNA1 protein modulates the alternative splicing of cellular genes","volume":"16","author":"Boudreault","year":"2019","journal-title":"Virol. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1093\/nar\/gkac272","article-title":"Reovirus \u00b52 protein modulates host cell alternative splicing by reducing protein levels of U5 snRNP core components","volume":"50","author":"Boudreault","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/liv.13641","article-title":"Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis b","author":"Buti","year":"2018","journal-title":"Liver Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/hep.31255","article-title":"Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis b","volume":"73","author":"Daffis","year":"2021","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1534\/genetics.113.160499","article-title":"Comparative genomics RNAi screen identifies Eftud2 as a novel regulator of innate immunity","volume":"197","author":"De Arras","year":"2014","journal-title":"Genetics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005841","article-title":"The dengue virus NS5 protein intrudes in the cellular spliceosome and modulates splicing","volume":"12","author":"De Maio","year":"2016","journal-title":"PloS Pathog."},{"key":"B10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrd2819","article-title":"Plerixafor","volume":"8","author":"DiPersio","year":"2009","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jhep.2020.01.011","article-title":"Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure","volume":"73","author":"Engelmann","year":"2020","journal-title":"J. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-13-2686","article-title":"A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer [published correction appears in clin cancer res","volume":"20","author":"Galsky","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jep.2018.06.005","article-title":"Anti-hepatitis b virus effects of the traditional Chinese herb artemisia capillaris and its active enynes","volume":"224","author":"Geng","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1128\/AAC.44.6.1667-1673.2000","article-title":"Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers","volume":"44","author":"Hendrix","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nm.3253","article-title":"Regulation of hepatic innate immunity by hepatitis c virus","volume":"19","author":"Horner","year":"2013","journal-title":"Nat. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis b","volume":"68","author":"Janssen","year":"2018","journal-title":"J. Hepatol."},{"key":"B17","first-page":"S757","article-title":"Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis b","volume":"75","author":"Janssen","year":"2021","journal-title":"J. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HbeAg-positive chronic hepatitis b: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3760\/cma.j.issn.1007-3418.2020.01.006","volume":"28","author":"Jia","year":"2020","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/cells8020185","article-title":"Involvement of CXCR4 in normal and abnormal development","volume":"8","author":"Kawaguchi","year":"2019","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.coviro.2018.04.006","article-title":"Perspectives and limitations for nucleo(t)side analogs in future HBV therapies","volume":"30","author":"Levrero","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11010-014-2020-8","article-title":"The SDF-1\/CXCR4 axis induces epithelial\u2013mesenchymal transition in hepatocellular carcinoma","volume":"392","author":"Li","year":"2014","journal-title":"Mol. Cell Biochem."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004199","article-title":"Cytoplasmic viral RNA-dependent RNA polymerase disrupts the intracellular splicing machinery by entering the nucleus and interfering with Prp8","volume":"10","author":"Liu","year":"2014","journal-title":"PloS Pathog."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1111\/jcmm.15202","article-title":"Hepatitis b virus-induced hyperactivation of b cells in chronic hepatitis b patients via TLR4","volume":"24","author":"Li","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"103149","DOI":"10.1016\/j.jri.2020.103149","article-title":"Spliceosome protein EFTUD2 is upregulated in the trophoblast of spontaneous miscarriage and hydatidiform mole","volume":"140","author":"L\u00f6b","year":"2020","journal-title":"J. Reprod. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1083\/jcb.201701165","article-title":"Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90\/R2TP chaperones","volume":"216","author":"Malinov\u00e1","year":"2017","journal-title":"J. Cell Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis b","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000537","article-title":"An integrated strategy to study muscle development and myofilament structure in caenorhabditis elegans","volume":"5","author":"Meissner","year":"2009","journal-title":"PloS Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.bbrc.2018.06.020","article-title":"Reno-Protective effects of TAK-242 on acute kidney injury in a rat model","volume":"503","author":"Mohammad","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"G244","DOI":"10.1152\/ajpgi.00366.2013","article-title":"Inhibition of toll-like receptor 4 suppresses liver injury induced by biliary obstruction and subsequent intraportal lipopolysaccharide injection","volume":"306","author":"Oya","year":"2014","journal-title":"Am. J. Physiol. Gastrointest Liver Physiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1535-7163.MCT-14-0850","article-title":"Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models","volume":"14","author":"Peng","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ebiom.2019.10.022","article-title":"Niacin analogue, 6-aminonicotinamide, a novel inhibitor of hepatitis b virus replication and HbsAg production","volume":"49","author":"Ren","year":"2019","journal-title":"EbioMedicine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-10-3143","article-title":"CXCL12\/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer","volume":"71","author":"Righi","year":"2011","journal-title":"Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12026-021-09188-2","article-title":"MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity","volume":"69","author":"Saikh","year":"2021","journal-title":"Immunol. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-020-2097-2","article-title":"Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug","volume":"22","author":"Samarpita","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.biopha.2016.09.036","article-title":"TAK-242 treatment ameliorates liver ischemia\/reperfusion injury by inhibiting TLR4 signaling pathway in a swine model of maastricht-category-III cardiac death","volume":"84","author":"Shao","year":"2016","journal-title":"BioMed. Pharmacother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1080\/08820139.2021.1970763","article-title":"Association of elongation factor tu GTP-binding domain-containing 2 gene (EFTUD2) polymorphism with the risk of hepatitis b virus infection","volume":"51","author":"Tian","year":"2022","journal-title":"Immunol. Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1534\/genetics.109.110171","article-title":"A genomewide RNAi screen for genes that affect the stability, distribution and function of p granules in caenorhabditis elegans","volume":"183","author":"Updike","year":"2009","journal-title":"Genetics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41431-020-0680-2","article-title":"Novel candidate genes in esophageal atresia\/tracheoesophageal fistula identified by exome sequencing","volume":"29","author":"Wang","year":"2021","journal-title":"Eur. J. Hum. Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.bbrc.2016.03.001","article-title":"TAK-242 attenuates acute cigarette smoke-induced pulmonary inflammation in mouse via the TLR4\/NF-\u03baB signaling pathway","volume":"472","author":"Wang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1053\/j.gastro.2018.07.057","article-title":"Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis b virus infection","volume":"156","author":"Xia","year":"2019","journal-title":"Gastroenterology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24440","article-title":"A novel de novo missense mutation in EFTUD2 identified by whole-exome sequencing in mandibulofacial dysostosis with microcephaly","volume":"36","author":"Yang","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S0618-8278(19)30084-2","article-title":"Ascending dose cohort study of inarigivir \u2013 a novel RIG I agonist in chronic HBV patients: final results of the ACHIEVE trial","volume":"70","author":"Yuen","year":"2019","journal-title":"J. Hepatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6608","DOI":"10.1128\/JVI.00364-15","article-title":"EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I\/MDA5 Pathway","volume":"89","author":"Zhu","year":"2015","journal-title":"Journal of virology"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1118801\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:21:09Z","timestamp":1676877669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1118801\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":44,"alternative-id":["10.3389\/fcimb.2023.1118801"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1118801","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"article-number":"1118801"}}